Astrazeneca PLC AZN
We take great care to ensure that the data presented and summarized in this overview for ASTRAZENECA PLC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AZN
View all-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.19 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.8 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.48 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.45 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.27 Billion0.45% of portfolio
-
Sanders Capital, LLC West Palm Beach, FL15MShares$998 Million1.7% of portfolio
-
Jennison Associates LLC15MShares$997 Million0.73% of portfolio
-
Morgan Stanley New York, NY12.8MShares$855 Million0.07% of portfolio
-
Goldman Sachs Group Inc New York, NY12MShares$803 Million0.16% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa10.5MShares$698 Million0.34% of portfolio
Latest Institutional Activity in AZN
Top Purchases
Top Sells
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Transactions at AZN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|